Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 135, Issue 10, Pages 2237-2248Publisher
WILEY
DOI: 10.1002/ijc.29080
Keywords
metabolism; oncometabolite; paraganglioma; pheochromocytoma; glioblastoma; SDH; FH; IDH; hypoxia; epigenetics
Categories
Funding
- Agence Nationale de la Recherche [ANR-2011-JCJC-00701 MODEOMAPP]
- European Union [259735]
- Programme Hospitalier de Recherche Clinique [COMETE 3 AOM 06 179]
- Plan Cancer Action (AAP Epigenetique et Cancer, U970-C13089KS-INSERM PLAN CANCER [3.2 2009-2013]
Ask authors/readers for more resources
Although the alteration of cellular metabolism in cancer was reported by Warburg in the early 1930s, a regain of interest in cancer metabolism has more recently followed the discovery of germline or somatic mutations in genes coding for metabolic enzymes (succinate dehydrogenase, fumarate hydratase and isocitrate dehydrogenase) that are associated with tumor susceptibility. Mutations in these genes are found in numerous tumor types including paragangliomas, kidney cancers, leiomyomas, glioblastomas and acute myeloid leukemia. They lead to the accumulation of so-called oncometabolites that behave as competitors of 2-oxoglutarate-dependent dioxygenases, involved in a broad spectrum of pathways such as hypoxic response and epigenetic reprogramming. Here, we review the diverse pathways affected by oncometabolites, their potential role in cancer formation, maintenance, metastasis and sensitivity to chemotherapies, as well as emerging new therapeutic strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available